跨心力衰竭类别的慢性无能症
Damiano Magrì1, Massimo Piepoli2,3, Giovanna Gallo1
1Department of Clinical and Molecular Medicine, Sapienza University of Rome; Rome - Italy.
European journal of preventive cardiology
|October 27, 2024
概括
在心力衰竭 (HF) 中,慢性无能 (CI) 与不良的运动能力和结果有关. 了解CI定义和管理策略对于改善患者预后至关重要.
科学领域:
- 心脏病学 心脏病学
- 自主神经系统研究 自主神经系统研究
- 心脏衰竭病理生理学 病理生理学
背景情况:
- 心力衰竭 (HF) 综合征涉及自主失衡和同情性多动性.
- 这导致心肌氧需求增加,氧化应激和外周血管收缩.
- 心脏β1受体的逐渐脱敏和下调有助于HF病理生理学.
研究的目的:
- 审查心力衰竭中慢性无能症 (CI) 的定义和临床影响.
- 讨论CI的药理学和非药理学治疗策略.
- 为了澄清某些药物的干扰与运动诱导的心率反应.
主要方法:
- 关于慢性无能症定义和影响的文献综述.
- 对高频率心率反应药理效应的分析.
- 讨论治疗干预措施来管理CI.
主要成果:
- 慢性无能症 (CI),定义为无法增加心率 (HR) 活动,与运动能力降低和HF更糟糕的预后相关.
- 药物制剂,特别是β-阻断剂,可以干扰生理HR反应,但可以改善HF结果.
- 速度适应节奏是一种争论的策略,用于管理运动诱导的HR反应.
结论:
- CI是HF的显著临床发现,影响运动能力和预后.
- 仔细考虑诸如β-阻断剂之类的药物是必不可少的,因为它们的益处超过了潜在的HR.
- 对CI有效的治疗策略进行进一步的研究是有必要的.
更多相关视频
相关概念视频
Heart Failure IV: Classification and Diagnostic Evaluation
1
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure I: Introduction
1
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1
Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
Heart Failure Drugs: Inotropic Agents
527
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
527


